OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Advanced Head and Neck Cancers-Looking Forward

home / peer-exchange / looking-forward-hnscc
Biology of Head and Neck Cancer

EP. 1: Biology of Head and Neck Cancer

August 10th 2017
Genetic Landscape of HNSCC

EP. 2: Genetic Landscape of HNSCC

August 10th 2017
Head and Neck Cancer and the AJCC 8th Edition

EP. 3: Head and Neck Cancer and the AJCC 8th Edition

August 10th 2017
Personalized Approaches to Head and Neck Cancer Therapy

EP. 4: Personalized Approaches to Head and Neck Cancer Therapy

August 10th 2017
De-Escalation of Therapy for HPV-Positive HNSCC

EP. 5: De-Escalation of Therapy for HPV-Positive HNSCC

August 10th 2017
Surgery for Locally Advanced HNSCC

EP. 6: Surgery for Locally Advanced HNSCC

August 10th 2017
The Role of Induction Chemotherapy in HNSCC

EP. 7: The Role of Induction Chemotherapy in HNSCC

August 10th 2017
Refining Chemoradiation for Advanced HNSCC

EP. 8: Refining Chemoradiation for Advanced HNSCC

August 10th 2017
New Therapies for HNSCC

EP. 9: New Therapies for HNSCC

August 10th 2017
Immunotherapy for HNSCC

EP. 10: Immunotherapy for HNSCC

August 10th 2017
Pseudoprogression on Immunotherapy in HNSCC

EP. 11: Pseudoprogression on Immunotherapy in HNSCC

August 10th 2017
Practical Issues Surrounding Immunotherapy for HNSCC

EP. 12: Practical Issues Surrounding Immunotherapy for HNSCC

August 10th 2017
Take-Home Messages: Immunotherapy for HNSCC

EP. 13: Take-Home Messages: Immunotherapy for HNSCC

August 10th 2017
Emerging Checkpoint Inhibitors for HNSCC

EP. 14: Emerging Checkpoint Inhibitors for HNSCC

August 10th 2017
Immunotherapy Combinations for HNSCC

EP. 15: Immunotherapy Combinations for HNSCC

August 10th 2017
Immunotherapy in the Peri-Operative Setting of HNSCC

EP. 16: Immunotherapy in the Peri-Operative Setting of HNSCC

August 10th 2017
Next Steps in Research for Immunotherapy for HNSCC

EP. 17: Next Steps in Research for Immunotherapy for HNSCC

August 10th 2017
Key Points for Treatment of Advanced HNSCC

EP. 18: Key Points for Treatment of Advanced HNSCC

August 10th 2017

Latest Conference Coverage

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

Hematologists Highlight Notable Insights From the 2025 EHA Congress

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact